Syntimmune appoints Pfizer, AbbVie veteran as new CMO
pharmafile | July 10, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AbbVie, CMO, John Hopkins University, Pfizer, Syntimmune
The Boston-based clinical biotechnology company Syntimmune has appointed Dr Mario Saltarelli as its Chief Medical Officer. Dr Saltarelli will take the role of current CMO Dr Donald Johns who will become the Executive Vice President of Medical and Scientific Affairs for Syntimmune.
Having earned both an MD and PhD in neurosciences from John Hopkins University School of Medicine, Dr Saltarelli brings to the role a variety of expertise developed through experiences in discovery research, clinical development, pipeline strategy and global regulatory operations.
“Mario’s deep expertise in drug development and strong leadership skills will be a tremendous asset to Syntimmune as we advance our pipeline of novel therapies targeting a broad range of autoimmune diseases,” said Dr Jean-Paul Kress, Syntimmune’s President and CEO. “We’re thrilled to have him on board to lead our medical organisation. I’d also like to thank Don for his support as acting CMO, and I’m pleased that he’ll be continuing to help Syntimmune strengthen our medical and scientific leadership position.”
Dr Saltarelli, who most recently served as Senior Vice President at Vertex, has in the past held leadership roles at Shire, AbbVie and Pfizer. His previous role at Vertex saw him manage clinical development projects across multiple therapeutic areas. Prior to Vertex, Dr Saltarelli had also served as CMO of Annexon Biosciences and as Senior Vice President and Chief Science Officer at Mallinckrodt Pharmaceuticals.
Saltarelli’s role at Vertex saw him manage clinical development projects across multiple therapeutic areas as Senior Vice President, Early Development and Neurology. Dr Saltarelli commented: “This is an exciting moment for Syntimmune, with multiple clinical trials underway and planned, and I am delighted to be able to contribute. Syntimmune has a strong vision of leveraging its unique insights into FcRn, honed over 25 years of research, to develop novel therapies that will truly help patients. I’m honoured to be part of the team.”
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Genmab to submit FDA application for lymphoma therapy
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the …
The National Institute for Health and Care Excellence announce technology appraisal guidance recommending risankizumab for adult patients with moderate to severe ulcerative colitis
The National Institute for Health and Care Excellence (NICE) have recommended adult patients in England …
